Ongoing trials, as reviewed by Ponce et al., include agents such as Dinaciclib (CDK2 inhibitor), Adavosertib (WEE1 inhibitor), Linsitinib (IGF‐1 receptor inhibitor), iP300w (p300/CBP inhibitor), anti‐DUX4 antibodies, and BCI (DUSP6 inhibitor) for CIC::DUX4 sarcomas [26]. This evidence concerns the gene DUX4 and sarcoma.